SOURCES SOUGHT
A -- Medicinal Chemistry Support Program for Therapeutic Development (MCSP)
- Notice Date
- 10/3/2016
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke, 6001 Executive Boulevard, Neuroscience Center, Suite 3287, MSC 9531, Bethesda, Maryland, 20892-9531
- ZIP Code
- 20892-9531
- Solicitation Number
- SBSS-NIH-NINDS-17-01
- Archive Date
- 11/12/2016
- Point of Contact
- Annette Carter, Phone: (301) 496-5916, Kirkland L. Davis, Phone: (301) 496-1813
- E-Mail Address
-
cartera@mail.nih.gov, kd17c@nih.gov
(cartera@mail.nih.gov, kd17c@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- SMALL BUSINESS SOURCES SOUGHT (SBSS) NOTICE NIH-NINDS-17-01 TITLE: Medicinal Chemistry Support Program for Therapeutic Development (MCSP) The National Institute of Neurological Disorders and Stroke (NINDS) and the NIH Blueprint Neurotherapeutics Network (BPN) (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm) have established a ‘virtual pharma' network of contract service providers and consultants with extensive industry experience to enable therapeutic (e.g., small molecule, peptide, biologic) development in the NIH research community. This network offers researchers access to a range of industry-style therapeutic development services and expertise, including medicinal chemistry, IND-enabling studies, and Phase 1 clinical trial infrastructure, with the goal of supporting efforts to advance compounds successfully through Phase 1 clinical testing. The Medicinal Chemistry Support Program for Therapeutic Development (MCSP) component will provide medicinal chemistry services including project management and reporting, compound logistics, synthesis, computational chemistry and in vitro absorption, distribution, metabolism, excretion and toxicology (ADMET) studies in support of preclinical drug discovery efforts supported by NIH, NINDS and its contributors. PURPOSE OF NOTICE The NINDS is seeking to identify small business concerns that possess the requisite capabilities and qualifications to provide a full range of medicinal chemistry services (exploratory, hit-to-lead and lead optimization phases) including SAR analysis and design, synthesis, in vitro ADMET, computational chemistry/Computer Aided Drug Discovery (CADD) and compound logistics of storage and shipping for the purposes of developing new therapeutics. The applicable NAICS code for this requirement is 541712. Therefore, the small business size standard for this requirement is 1,000 or fewer employees. Small businesses that meet the applicable size standard above and who believe that they possess the requisite capabilities, capacity, and personnel with the experience and qualifications to provide the full range of medicinal chemistry services described above are asked to address each of the areas described in the Program Requirement section below and to submit a response. Please ensure that your response is complete and sufficiently detailed to assist in our evaluation as to whether or not this requirement could be set-aside for small business participation only. If your business concern is NOT a small business, there is no need to respond to this announcement. If responses indicate a reasonable expectation of obtaining competitive offers from two or more responsible and capable small business concerns, any subsequent requirement may be set-aside for small business participation only. PROGRAM REQUIREMENT The NINDS requires a full service, turn-key medicinal chemistry operation for the development of therapeutics within the mission of NINDS, BPN and other NIH Institutes. This operation would support a range of medicinal chemistry services (exploratory, hit-to-lead and lead optimization phases) including SAR analysis and design, synthesis, in vitro ADMET, computational chemistry/Computer Aided Drug Discovery (CADD) and compound logistics of storage and shipping. An organization must have the capacity to conduct from 1-10 projects simultaneously in the three phases (exploratory, hit-to-lead, lead optimization). Those responding will need to address the availability of sufficient professional and technical personnel and the capability to rapidly scale up or down the number of staff dedicated to the MCSP contract, depending on the number of projects underway at any given time. Responses to this notice MUST address/provide the following information: (a) Current in-house capability and capacity to perform medicinal chemistry services (exploratory, hit-to-lead and lead optimization phases) including SAR analysis and design, synthesis, in vitro ADMET, computational chemistry/Computer Aided Drug Discovery (CADD) and compound logistics of storage and shipping for 1-10 concurrent projects; (b) Demonstrated experience and success in providing a flexible medicinal chemistry support program optimizing compounds from hits into pre-clinical lead candidates by addressing a broad range of chemical liabilities, including toxicity, low blood-brain barrier penetrability, and metabolic instability by providing routine in vitro pharmacology and toxicology assays and services; (c) Demonstrated capability for productive collaborations with organizations and researchers involved in therapeutic development; (d) Staffing and personnel qualifications, i.e., numbers, availability and type of staff that could be assigned to such a program; their expertise, experience and education, including citation of any formal training; (e) A discussion of the requirements to be performed in-house versus those performed outside the responding organization; and (f) Your organization's name, address and DUNS number; point of contact, including title, telephone number, and email address; and your current small business size status (e.g., small, small disadvantaged business, HUBZone, women-owned, 8(a), veteran-owned, etc. pursuant to the applicable NAICS code 541712. GENERIC MARKETING BROCHURES/CAPABILITY STATEMENTS WILL NOT BE EVALUATED. Please submit one (1) electronic copy of your response via e-mail to Ms. Annette Carter, Contracting Officer, at cartera@mail.nih.gov and one copy to Mr. Kirkland L. Davis, Contracting Officer, at kd17c@nih.gov in MS Word (doc, docx) or Adobe Portable Document Format (PDF). The e-mail subject line must specify SBSS-NIH-NINDS-17-01. You are encouraged to limit your response to fewer than 15 pages. ALL RESPONSES ARE DUE BY 4:00 PM EASTERN STANDARD TIME ON October 28, 2016. This Small Business Sources Sought Announcement is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Government. The Government does not intend to award a contract on the basis of responses nor otherwise pay for the preparation of any information submitted or the Government's use of such information. Acknowledgment of receipt of responses will not be made, nor will respondents be notified of the Government's evaluation of the information received. Responses will be held in a confidential manner. Any proprietary information should be so marked. Contracting Office Address: NINDS R&D CMB, NIDA, NIH 6001 Executive Boulevard, Suite 3287 Bethesda, Maryland 20892 United States Primary Point of Contact: Annette Carter, Contract Specialist cartera@mail.nih.gov Phone: (301) 496-1813 Secondary Point of Contact: Kirkland L. Davis, Contracting Officer kd17c@nih.gov Phone: (301) 496-1813
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NINDS/SBSS-NIH-NINDS-17-01/listing.html)
- Record
- SN04296320-W 20161005/161003234512-54c20336d243bca5751d4859a0f549bb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |